<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rpmj</journal-id><journal-title-group><journal-title xml:lang="ru">Research'n Practical Medicine Journal</journal-title><trans-title-group xml:lang="en"><trans-title>Research and Practical Medicine Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2410-1893</issn><publisher><publisher-name>"QUASAR", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17709/2409-2231-2019-6-2-7</article-id><article-id custom-type="elpub" pub-id-type="custom">rpmj-401</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Обзор</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Review</subject></subj-group></article-categories><title-group><article-title>ФАКТОРЫ ПРОГНОЗА РЕЗЕКТАБЕЛЬНОГО РАКА ОБЩЕГО ЖЕЛЧНОГО ПРОТОКА</article-title><trans-title-group xml:lang="en"><trans-title>PROGNOSTIC FACTORS FOR RESECTABLE COMMON BILE DUCT CANCER</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7163-2089</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сыскова</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Syskova</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант кафедры онкологии и лучевой терапии лечебного факультета;   аспирант отделения опухолей печени и поджелудочной железы</p><p>117997,  г. Москва, ул. Островитянова, д. 1;   115478, Москва, Каширское шоссе, д. 23</p></bio><bio xml:lang="en"><p>PhD student, department of oncology and radiation therapy, faculty of therapy; , graduate student in the department of liver and pancreas tumors</p><p>1 Ostrovityanova str., Moscow 1 17997; 23 Kashirskoe sh., 1 15478</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Стилиди</surname><given-names>И. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Stilidi</surname><given-names>I. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>член-корреспондент РАН, д. м.н., профессор, заведующий кафедрой онкологии и лучевой терапии лечебного факультета ;  директор </p><p>117997,  г. Москва, ул. Островитянова, д. 1;   115478, Москва, Каширское шоссе, д. 23</p></bio><bio xml:lang="en"><p>corr. member of RAS, MD, PhD, DSc, professor, head of the department of oncology and radiotherapy of the medical faculty ; Director</p><p>1 Ostrovityanova str., Moscow 1 17997; 23 Kashirskoe sh., 1 15478</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5348-5011</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Поляков</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Polyakov</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p> к. м.н., старший научный сотрудник отделения опухолей печени и поджелудочной железы </p><p>115478, Москва, Каширское шоссе, д. 23</p></bio><bio xml:lang="en"><p>MD, PhD, senior researcher, department of liver and pancreas tumors</p><p>23 Kashirskoe sh., 1 15478</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Министерства здравоохранения Российской Федерации;  ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н.Блохина» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University (RNRMU) of the Health Ministry of Russia; N.N.BLokhin National Medical Research Centre of Oncology of the Health Ministry of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н.Блохина» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.N.BLokhin National Medical Research Centre of Oncology of the Health Ministry of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>27</day><month>06</month><year>2019</year></pub-date><volume>6</volume><issue>2</issue><fpage>69</fpage><lpage>74</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сыскова А.Ю., Стилиди И.С., Поляков А.Н., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Сыскова А.Ю., Стилиди И.С., Поляков А.Н.</copyright-holder><copyright-holder xml:lang="en">Syskova A.Y., Stilidi I.S., Polyakov A.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpmj.ru/rpmj/article/view/401">https://www.rpmj.ru/rpmj/article/view/401</self-uri><abstract><p>Рак общего желчного протока – редкое злокачественное заболевание с неблагоприятным прогнозом. Пятилетняя общая выживаемость составляет 18–48%, и более половины пациентов подвержены рецидиву в течение пяти лет.</p><p>Метастазы в регионарных лимфоузлах и наличие опухолевых клеток в крае резекции – независимые факторы негативного прогноза, ассоциирующиеся с высоким риском возникновения рецидива. Клиническая значимость других факторов прогноза, таких как периневральная инвазия, низкая степень дифференцировки, размер опухоли, инвазия в поджелудочную железу и необходимость выполнения резекции смежных органов, требует дальнейшего изучения.</p></abstract><trans-abstract xml:lang="en"><p>Common bile duct cancer is a rare malignant disease with a poor prognosis. Five-year overall survival is 18-48%, and more than half of the patients relapse within five years.</p><p>Metastases in the regional lymph nodes and the presence of tumor cells in the margin of the resection are independent factors of a negative prognosis and are associated with a high risk of recurrence.</p><p>The clinical significance of other prognostic factors, such as renal invasion, low degree of differentiation, tumor size, pancreatic invasion and the need for resection of adjacent organs, require further study.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>рак общего желчного протока</kwd><kwd>холангиокарционома</kwd><kwd>факторы прогноза</kwd><kwd>хирургическое лечение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>ommon bile duct cancer</kwd><kwd>choLangiocarcinoma</kwd><kwd>prognostic factors</kwd><kwd>surgical treatment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou Y, Liu S, Wu L, Wan T. Survival after surgical resection of distal cholangiocarcinoma: A systematic review and meta-analy¬sis of prognostic factors. Asian J Surg. 2017 Apr;40 (2):129-138. DOI: 10.1016/j.asjsur.2015.07.002</mixed-citation><mixed-citation xml:lang="en">Zhou Y, Liu S, Wu L, Wan T. Survival after surgical resection of distal cholangiocarcinoma: A systematic review and meta-analy¬sis of prognostic factors. Asian J Surg. 2017 Apr;40 (2):129-138. DOI: 10.1016/j.asjsur.2015.07.002</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ethun CG, Lopez-Aguiar AG, Pawlik TM, Poultsides G, Idrees K, Fields RC, et al. Distal Cholangiocarcinoma and Pancreas Adeno¬carcinoma: Are They Really the Same Disease? A 13-Institution Study from the US Extrahepatic Biliary Malignancy Consortium and the Central Pancreas Consortium. J Am Coll Surg. 2017 Apr;224 (4):406—413. DOI: 10.1016/j.jamcollsurg.2016.12.006</mixed-citation><mixed-citation xml:lang="en">Ethun CG, Lopez-Aguiar AG, Pawlik TM, Poultsides G, Idrees K, Fields RC, et al. Distal Cholangiocarcinoma and Pancreas Adeno¬carcinoma: Are They Really the Same Disease? A 13-Institution Study from the US Extrahepatic Biliary Malignancy Consortium and the Central Pancreas Consortium. J Am Coll Surg. 2017 Apr;224 (4):406—413. DOI: 10.1016/j.jamcollsurg.2016.12.006</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Petrova E, Ruckert F, Zach S, Shen Y, Weitz J, Grutzmann R, et al. Survival outcome and prognostic factors after pancreato-duodenectomy for distal bile duct carcinoma: a retrospective multicenter study. Langenbecks Arch Surg. 2017 Aug;402 (5):831- 840. DOI: 10.1007/s00423—017—1590—9.</mixed-citation><mixed-citation xml:lang="en">Petrova E, Ruckert F, Zach S, Shen Y, Weitz J, Grutzmann R, et al. Survival outcome and prognostic factors after pancreato-duodenectomy for distal bile duct carcinoma: a retrospective multicenter study. Langenbecks Arch Surg. 2017 Aug;402 (5):831- 840. DOI: 10.1007/s00423—017—1590—9.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015 Apr;29 (2):221-32. DOI: 10.1016/j.bpg.2015.02.003</mixed-citation><mixed-citation xml:lang="en">Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015 Apr;29 (2):221-32. DOI: 10.1016/j.bpg.2015.02.003</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А. Д., Старинский В. В., Петрова Г. В. Злокачествен-ные новообразования в России в 2016 году. М.: МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018./Kaprin AD, Starinskii VV, Petrova GV. Malignant neoplasms in Russia in 2016. Moscow: P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation, 2018. (In Russian).</mixed-citation><mixed-citation xml:lang="en">Каприн А. Д., Старинский В. В., Петрова Г. В. Злокачествен-ные новообразования в России в 2016 году. М.: МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018./Kaprin AD, Starinskii VV, Petrova GV. Malignant neoplasms in Russia in 2016. Moscow: P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation, 2018. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Komaya K, Ebata T, Shirai K, Ohira S, Morofuji N, Akutagawa A, et al. Recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg. 2017 Mar;104 (4):426-433. DOI: 10.1002/bjs.10452</mixed-citation><mixed-citation xml:lang="en">Komaya K, Ebata T, Shirai K, Ohira S, Morofuji N, Akutagawa A, et al. Recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg. 2017 Mar;104 (4):426-433. DOI: 10.1002/bjs.10452</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Andrianello S, Paiella S, Allegrini V, Ramera M, Pulvirenti A, Malleo G, et al. Pancreaticoduodenectomy for distal cholangio-carcinoma: surgical results, prognostic factors, and long-term follow-up. Langenbecks Arch Surg. 2015 Jul;400 (5):623-8. DOI: 10.1007/s00423—015—1320—0.</mixed-citation><mixed-citation xml:lang="en">Andrianello S, Paiella S, Allegrini V, Ramera M, Pulvirenti A, Malleo G, et al. Pancreaticoduodenectomy for distal cholangio-carcinoma: surgical results, prognostic factors, and long-term follow-up. Langenbecks Arch Surg. 2015 Jul;400 (5):623-8. DOI: 10.1007/s00423—015—1320—0.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kim B, Kim K, Chie E, Kwon J, Jang JY, Kim SW, et al. Long-Term Outcome of Distal Cholangiocarcinoma after Pancreaticoduo¬denectomy Followed by Adjuvant Chemoradiotherapy: A 15-Year Experience in a Single Institution. Cancer Res Treat. 2017 Apr;49 (2):473—483. DOI: 10.4143/crt.2016.166</mixed-citation><mixed-citation xml:lang="en">Kim B, Kim K, Chie E, Kwon J, Jang JY, Kim SW, et al. Long-Term Outcome of Distal Cholangiocarcinoma after Pancreaticoduo¬denectomy Followed by Adjuvant Chemoradiotherapy: A 15-Year Experience in a Single Institution. Cancer Res Treat. 2017 Apr;49 (2):473—483. DOI: 10.4143/crt.2016.166</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kim N, Lee H, Min S, Lee H. Bile duct segmental resection ver¬sus pancreatoduodenectomy for middle and distal common bile duct cancer. Ann Surg Treat Res. 2018 May;94 (5):240-246. DOI: 10.4174/astr.2018.94.5.240</mixed-citation><mixed-citation xml:lang="en">Kim N, Lee H, Min S, Lee H. Bile duct segmental resection ver¬sus pancreatoduodenectomy for middle and distal common bile duct cancer. Ann Surg Treat Res. 2018 May;94 (5):240-246. DOI: 10.4174/astr.2018.94.5.240</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ecker B, Vining C, Roses R, Maggino L, Lee MK, Drebin JA, et al. Identification of Patients for Adjuvant Therapy After Resection of Carcinoma of the Extrahepatic Bile Ducts: A Propensity Score- Matched Analysis. Ann Surg Oncol. 2017 Dec;24 (13):3926-3933. DOI: 10.1245/s10434—017—6095—9</mixed-citation><mixed-citation xml:lang="en">Ecker B, Vining C, Roses R, Maggino L, Lee MK, Drebin JA, et al. Identification of Patients for Adjuvant Therapy After Resection of Carcinoma of the Extrahepatic Bile Ducts: A Propensity Score- Matched Analysis. Ann Surg Oncol. 2017 Dec;24 (13):3926-3933. DOI: 10.1245/s10434—017—6095—9</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hester C, Nassour I, Adams-Huet B et al. Improved Survival in Surgically Resected Distal Cholangiocarcinoma Treated with Adju¬vant Therapy: a Propensity Score Matched Analysis. J Gastrointest Surg. 2018 Dec;22 (12):2080-2087. DOI: 10.1007/s11605-018- 3875-x</mixed-citation><mixed-citation xml:lang="en">Hester C, Nassour I, Adams-Huet B et al. Improved Survival in Surgically Resected Distal Cholangiocarcinoma Treated with Adju¬vant Therapy: a Propensity Score Matched Analysis. J Gastrointest Surg. 2018 Dec;22 (12):2080-2087. DOI: 10.1007/s11605-018- 3875-x</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kim H, Kim C, Hur Y, Koh YS, Kim JC, Kim HJ, Cho CK. The prognostic factors for survival after curative resection of distal cholangiocarcinoma: perineural invasion and lympho- vascular invasion. Surg Today. 2014 Oct;44 (10):1879-86. DOI: 10.1007/s00595—014—0846-z</mixed-citation><mixed-citation xml:lang="en">Kim H, Kim C, Hur Y, Koh YS, Kim JC, Kim HJ, Cho CK. The prognostic factors for survival after curative resection of distal cholangiocarcinoma: perineural invasion and lympho- vascular invasion. Surg Today. 2014 Oct;44 (10):1879-86. DOI: 10.1007/s00595—014—0846-z</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Chung Y, Choi D, Choi S, Heo J, Kim D. Prognostic factors fol¬lowing surgical resection of distal bile duct cancer. J Korean Surg Soc. 2013 Nov;85 (5):212-8. DOI: 10.4174/jkss.2013.85.5.212.</mixed-citation><mixed-citation xml:lang="en">Chung Y, Choi D, Choi S, Heo J, Kim D. Prognostic factors fol¬lowing surgical resection of distal bile duct cancer. J Korean Surg Soc. 2013 Nov;85 (5):212-8. DOI: 10.4174/jkss.2013.85.5.212.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Wellner U, Shen Y, Keck T, Jin W, Xu Z. The survival outcome and prognostic factors for distal cholangiocarcinoma following surgi¬cal resection: a meta-analysis for the 5-year survival. Surg Today. 2017 Mar;47 (3):271-279. DOI: 10.1007/s00595-016-1362-0</mixed-citation><mixed-citation xml:lang="en">Wellner U, Shen Y, Keck T, Jin W, Xu Z. The survival outcome and prognostic factors for distal cholangiocarcinoma following surgi¬cal resection: a meta-analysis for the 5-year survival. Surg Today. 2017 Mar;47 (3):271-279. DOI: 10.1007/s00595-016-1362-0</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">DeOliveira M, Cunningham S, CameronJ, KamangarF, WinterJM, Lillemoe KD, et al. Cholangiocarcinoma. Ann Surg. 2007 May;245 (5):755—62. DOI: 10.1097/01.sla.0000251366.62632.d3</mixed-citation><mixed-citation xml:lang="en">DeOliveira M, Cunningham S, CameronJ, KamangarF, WinterJM, Lillemoe KD, et al. Cholangiocarcinoma. Ann Surg. 2007 May;245 (5):755—62. DOI: 10.1097/01.sla.0000251366.62632.d3</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Tan X, Xiao K, Liu W, Chang S, Zhang T, Tang H. Prognostic factors of distal cholangiocarcinoma after curative surgery: a series of 84 cases. Hepatogastroenterology. 2013 Nov-Dec;60 (128):1892—5.</mixed-citation><mixed-citation xml:lang="en">Tan X, Xiao K, Liu W, Chang S, Zhang T, Tang H. Prognostic factors of distal cholangiocarcinoma after curative surgery: a series of 84 cases. Hepatogastroenterology. 2013 Nov-Dec;60 (128):1892—5.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Murakami Y, Uemura K, Hayashidani Y, Sudo T, Ohge H, Sue- da T. Pancreatoduodenectomy for Distal Cholangiocarcinoma: Prognostic Impact of Lymph Node Metastasis. World J Surg. 2007 Feb;31 (2):337-42; discussion 343-4. DOI: 10.1007/s00268- 006-0224-0</mixed-citation><mixed-citation xml:lang="en">Murakami Y, Uemura K, Hayashidani Y, Sudo T, Ohge H, Sue- da T. Pancreatoduodenectomy for Distal Cholangiocarcinoma: Prognostic Impact of Lymph Node Metastasis. World J Surg. 2007 Feb;31 (2):337-42; discussion 343-4. DOI: 10.1007/s00268- 006-0224-0</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Lad N, Kooby D. Distal Cholangiocarcinoma. Surg Oncol Clin N Am. 2014 Apr;23 (2):265-87. DOI: 10.1016/j.soc.2013.11.001.</mixed-citation><mixed-citation xml:lang="en">Lad N, Kooby D. Distal Cholangiocarcinoma. Surg Oncol Clin N Am. 2014 Apr;23 (2):265-87. DOI: 10.1016/j.soc.2013.11.001.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Chua T, Mittal A, Arena J, Sheen A, Gill A, Samra J. Resection margin influences survival after pancreatoduodenectomy for dis¬tal cholangiocarcinoma. Am J Surg. 2017 Jun;213 (6):1072-1076. DOI: 10.1016/j.amjsurg.2016.09.049</mixed-citation><mixed-citation xml:lang="en">Chua T, Mittal A, Arena J, Sheen A, Gill A, Samra J. Resection margin influences survival after pancreatoduodenectomy for dis¬tal cholangiocarcinoma. Am J Surg. 2017 Jun;213 (6):1072-1076. DOI: 10.1016/j.amjsurg.2016.09.049</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Park Y, Hwang D, Kim J, Lee J, Song K, Shin S, et al. The Prog¬nostic comparison of the longitudinal margin status in distal bile duct cancer: R0 on first bile duct resection vs. R0 after additional resection. J Hepatobiliary Pancreat Sci. 2019 May;26 (5):169-178. doi: 10.1002/jhbp.619</mixed-citation><mixed-citation xml:lang="en">Park Y, Hwang D, Kim J, Lee J, Song K, Shin S, et al. The Prog¬nostic comparison of the longitudinal margin status in distal bile duct cancer: R0 on first bile duct resection vs. R0 after additional resection. J Hepatobiliary Pancreat Sci. 2019 May;26 (5):169-178. doi: 10.1002/jhbp.619</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Courtin-Tanguy L, Turrini O, Bergeat D, Truant S, Darnis B, Delpero JR, et al. Multicentre study of the impact of factors that may affect long-term survival following pancreaticoduodenec-tomy for distal cholangiocarcinoma. HPB (Oxford). 2018 May;20 (5):405-410. DOI: 10.1016/j.hpb.2017.10.016</mixed-citation><mixed-citation xml:lang="en">Courtin-Tanguy L, Turrini O, Bergeat D, Truant S, Darnis B, Delpero JR, et al. Multicentre study of the impact of factors that may affect long-term survival following pancreaticoduodenec-tomy for distal cholangiocarcinoma. HPB (Oxford). 2018 May;20 (5):405-410. DOI: 10.1016/j.hpb.2017.10.016</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Courtin-Tanguy L, Rayar M, Bergeat D, Merdrignac A, Har¬noy Y, Boudjema K, et al. The true prognosis of resected distal cholangiocarcinoma. J Surg Oncol. 2016 Apr;113 (5):575-80. DOI: 10.1002/jso.24165</mixed-citation><mixed-citation xml:lang="en">Courtin-Tanguy L, Rayar M, Bergeat D, Merdrignac A, Har¬noy Y, Boudjema K, et al. The true prognosis of resected distal cholangiocarcinoma. J Surg Oncol. 2016 Apr;113 (5):575-80. DOI: 10.1002/jso.24165</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Ma L, Qiu J, Zhang Y, Qiu T, Wang B, Chen W, et al. Prognostic factors for operable biliary tract cancer: serum levels of lactate dehydrogenase, a strong association with survival. Onco Targets Ther. 2018 May 4;11:2533-2543. DOI: 10.2147/OTT.S150502</mixed-citation><mixed-citation xml:lang="en">Ma L, Qiu J, Zhang Y, Qiu T, Wang B, Chen W, et al. Prognostic factors for operable biliary tract cancer: serum levels of lactate dehydrogenase, a strong association with survival. Onco Targets Ther. 2018 May 4;11:2533-2543. DOI: 10.2147/OTT.S150502</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Kato Y, Takahashi S, Gotohda N, Konishi M. Prognostic Im-pact of the Initial Postoperative CA19-9 Level in Patients with Extrahepatic Bile Duct Cancer. J Gastrointest Surg. 2016 Aug;20 (8):1435-43. DOI: 10.1007/s11605-016-3180-5</mixed-citation><mixed-citation xml:lang="en">Kato Y, Takahashi S, Gotohda N, Konishi M. Prognostic Im-pact of the Initial Postoperative CA19-9 Level in Patients with Extrahepatic Bile Duct Cancer. J Gastrointest Surg. 2016 Aug;20 (8):1435-43. DOI: 10.1007/s11605-016-3180-5</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Bolm L, Petrova E, Weitz J, Rückert F, Wittel UA, Makowiec F, et al. Prognostic relevance of preoperative bilirubin-adjusted se¬rum carbohydrate antigen 19-9 in a multicenter subset analysis of 179 patients with distal cholangiocarcinoma. HPB (Oxford). 2019 Apr 5. pii: S1365-182X (19)30486-1. DOI: 10.1016/j. hpb.2019.03.363.</mixed-citation><mixed-citation xml:lang="en">Bolm L, Petrova E, Weitz J, Rückert F, Wittel UA, Makowiec F, et al. Prognostic relevance of preoperative bilirubin-adjusted se¬rum carbohydrate antigen 19-9 in a multicenter subset analysis of 179 patients with distal cholangiocarcinoma. HPB (Oxford). 2019 Apr 5. pii: S1365-182X (19)30486-1. DOI: 10.1016/j. hpb.2019.03.363.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Lopez-Aguiar A, Ethun C, Pawlik T, Tran T, Poultsides G, Isom C, et al. Association of Perioperative Transfusion with Recurrence and Survival After Resection of Distal Cholangiocarcinoma: A 10-Institution Study from the US Extrahepatic Biliary Malignancy Consortium. Ann Surg Oncol. 2019 Jun;26 (6):1814-1823. DOI: 10.1245/s10434-019-07306-x.</mixed-citation><mixed-citation xml:lang="en">Lopez-Aguiar A, Ethun C, Pawlik T, Tran T, Poultsides G, Isom C, et al. Association of Perioperative Transfusion with Recurrence and Survival After Resection of Distal Cholangiocarcinoma: A 10-Institution Study from the US Extrahepatic Biliary Malignancy Consortium. Ann Surg Oncol. 2019 Jun;26 (6):1814-1823. DOI: 10.1245/s10434-019-07306-x</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
